Review





Similar Products

braf multitarget tki (vegfr, raf, pdgfr)  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals braf multitarget tki (vegfr, raf, pdgfr)
Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, <xref ref-type= 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21 " width="250" height="auto" />
Braf Multitarget Tki (Vegfr, Raf, Pdgfr), supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multitarget+vegfr-tkis/braf+multitarget+tki++vegfr++raf++pdgfr+/pmc09674888-28-4-5
Average 90 stars, based on 1 article reviews
braf multitarget tki (vegfr, raf, pdgfr) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
multitarget vegfr-tkis  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals multitarget vegfr-tkis
Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, <xref ref-type= 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21 " width="250" height="auto" />
Multitarget Vegfr Tkis, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multitarget+vegfr-tkis/multitarget+vegfr+tkis/pmc08315452-181-12-14
Average 90 stars, based on 1 article reviews
multitarget vegfr-tkis - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
vegfr-tki multitarget  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals vegfr-tki multitarget
Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, <xref ref-type= 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21 " width="250" height="auto" />
Vegfr Tki Multitarget, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multitarget+vegfr-tkis/vegfr+tki+multitarget/pmc06708252-3-1-2
Average 90 stars, based on 1 article reviews
vegfr-tki multitarget - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, <xref ref-type= 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21 " width="100%" height="100%">

Journal: ESMO Open

Article Title: Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?

doi: 10.1016/j.esmoop.2022.100638

Figure Lengend Snippet: Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21

Article Snippet: , Vemurafenib Sorafenib , BRAF Multitarget TKI (VEGFR, RAF, PDGFR...) , No , M, L ≥3, KRAS G12D mutation , II , Recruiting NCT05068752.

Techniques: Homologous Recombination, Control

Selected ongoing clinical trials evaluating targeted therapies as monotherapy in metastatic PDAC

Journal: ESMO Open

Article Title: Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?

doi: 10.1016/j.esmoop.2022.100638

Figure Lengend Snippet: Selected ongoing clinical trials evaluating targeted therapies as monotherapy in metastatic PDAC

Article Snippet: , Vemurafenib Sorafenib , BRAF Multitarget TKI (VEGFR, RAF, PDGFR...) , No , M, L ≥3, KRAS G12D mutation , II , Recruiting NCT05068752.

Techniques: Clinical Proteomics, Mutagenesis, Expressing